Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm’s businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia.
G. Steven Burrill founded Burrill & Company as a logical extension of his 40-year involvement in the growth and prosperity of the biotechnology industry. Mr. Burrill has been an active advisor and catalyst in some of the industry’s most notable companies and transactions. Mr. Burrill’s close involvement and respected position within the industry has positioned the firm as a prominent deal-maker and facilitator of industry partnerships and alliances, all of which fosters a robust deal flow. Further contributing to this deal flow are: the scientific and business networks of its investment team; the Advisory Boards; the strategic and financial network of its limited partners; and the close relationships developed with numerous life science companies and management as a result of Burrill’s visibility, reputation, and the firm’s partnering and alliance work.
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here